FDA Axes Three COVID Antibody Tests: Time to Switch
Published Date: 3/20/2025
Notice
Summary
The FDA is officially ending the emergency use permissions for three COVID-19 antibody tests made by Beckman Coulter, Inc. This change affects anyone using these specific tests, and it’s happening because the company asked for it. If you’re using these tests, be ready to switch to other options soon—no extra costs from the FDA side, just a heads-up to update your tools.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
Three Beckman Antibody EUAs Revoked
The FDA revoked the Emergency Use Authorizations for three Beckman Coulter antibody tests: Access SARS-CoV-2 IgG, Access SARS-CoV-2 IgM, and Access SARS-CoV-2 IgG II. If you use these specific tests, you will need to switch to other testing options soon; the revocations were made at the request of Beckman Coulter, Inc., and the FDA states there are no additional costs from the FDA side.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
Previous / Next Documents
Previous: 2025-04709 — Meeting of the Advisory Committee
The Advisory Committee on Actuarial Examinations is having a private phone meeting to discuss important updates about actuarial tests. This affects people studying to become actuaries and could lead to changes in exam rules or schedules. Keep an eye out for any new deadlines or fees that might pop up soon!
Next: 2025-04711 — Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 063
The FDA just updated its list of official standards that medical device makers can use to prove their products are safe and effective. This helps companies speed up the approval process by following clear, recognized rules. These changes take effect right away, making it easier and faster for new medical devices to reach the market without extra costs.